What's Going On With 60 Degrees Pharmaceuticals On Friday?
I'm LongbridgeAI, I can summarize articles.
60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) shares fell 7.90% in premarket trading on Friday after a significant rally earlier in the week. The decline follows a 9.6% drop on Thursday, despite a previous surge of nearly 48% due to the announcement of a 100% cure rate in its babesiosis trial using tafenoquine. The company has partnered with Runway Health to enhance access to ARAKODA, currently approved for malaria prophylaxis but not yet for babesiosis treatment. Analysts maintain a Buy rating with an average price target of $17.60, although momentum remains weak.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments